Palbociclib in hormone-receptor-positive advanced breast cancer
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Growth of hormone-receptor-positive breast cancer is dependent on cyclin-dependent kinases 4 and 6 (CDK4 and CDK6), which promote progression from the G1 phase to the S phase of the cell cycle. We assessed the efficacy of palbociclib (an inhibitor of CDK4 and CDK6) and fulvestrant in advanced breast cancer. METHODS: This phase 3 study involved 521 patients with advanced hormone-receptor-positive, human epidermal growth factor receptor 2-negative breast cancer that had relapsed or progressed during prior endocrine therapy. We randomly assigned patients in a 2:1 ratio to receive palbociclib and fulvestrant or placebo and fulvestrant. Premenopausal or perimenopausal women also received goserelin. The primary end point was investigator-assessed progression-free survival. Secondary end points included overall survival, objective response, rate of clinical benefit, patient-reported outcomes, and safety. A preplanned interim analysis was performed by an independent data and safety monitoring committee after 195 events of disease progression or death had occurred. RESULTS: The median progression-free survival was 9.2 months (95% confidence interval [CI], 7.5 to not estimable) with palbociclib-fulvestrant and 3.8 months (95% CI, 3.5 to 5.5) with placebo-fulvestrant (hazard ratio for disease progression or death, 0.42; 95% CI, 0.32 to 0.56; P<0.001). The most common grade 3 or 4 adverse events in the palbociclib-fulvestrant group were neutropenia (62.0%, vs. 0.6% in the placebo-fulvestrant group), leukopenia (25.2% vs. 0.6%), anemia (2.6% vs. 1.7%), thrombocytopenia (2.3% vs. 0%), and fatigue (2.0% vs. 1.2%). Febrile neutropenia was reported in 0.6% of palbociclib-treated patients and 0.6% of placebo-treated patients. The rate of discontinuation due to adverse events was 2.6% with palbociclib and 1.7% with placebo. CONCLUSIONS: Among patients with hormone-receptor-positive metastatic breast cancer who had progression of disease during prior endocrine therapy, palbociclib combined with fulvestrant resulted in longer progression-free survival than fulvestrant alone. (Funded by Pfizer; PALOMA3 ClinicalTrials.gov number, NCT01942135.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“an interim analysis reported PFS of 9.2 months with palbociclib-fulvestrant and 3.8 months with placebo-fulvestrant (hazard ratio 0.42)”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [84]
In the citing paper
“This study enrolled pre- and peri-menopausal patients, with benefit of the combination observed across groups.”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [84]
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
Baselga, J., Campone, M., Piccart, M., Burris, H. A., Rugo, H. S., Sahmoud, T., Noguchi, S., Gnant, M., Pritchard, K. I., Lebrun, F., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109653 · Cited by 2,863
Finn, R. S., Crown, J. P., Lang, I., Boer, K., Bondarenko, I. M., Kulyk, S. O., Ettl, J., Patel, R., Pinter, T., Schmidt, M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71159-3 · Cited by 1,900
Self-citationThe history and future of targeting cyclin-dependent kinases in cancer therapy
Asghar, U., Witkiewicz, A. K., Turner, N. C., & Knudsen, E. S. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4504 · Cited by 1,767
Self-citationFinn, R. S., Dering, J., Conklin, D., Kalous, O., Cohen, D. J., Desai, A. J., Ginther, C., Atefi, M., Chen, I., Fowst, C., et al. (2009) · Breast Cancer Research · doi:10.1186/bcr2419 · Cited by 1,398
Cyclin D as a therapeutic target in cancer
Musgrove, E. A., Caldon, C. E., Barraclough, J., Stone, A., & Sutherland, R. L. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3090 · Cited by 1,370
ESR1 ligand-binding domain mutations in hormone-resistant breast cancer
Toy, W., Shen, Y., Won, H., Green, B., Sakr, R. A., Will, M., Li, Z., Gala, K., Fanning, S., King, T. A., et al. (2013) · Nature Genetics · doi:10.1038/ng.2822 · Cited by 1,248
Activating ESR1 mutations in hormone-resistant metastatic breast cancer
Robinson, D. R., Wu, Y.-M., Vats, P., Su, F., Lonigro, R. J., Cao, X., Kalyana-Sundaram, S., Wang, R., Ning, Y., Hodges, L., et al. (2013) · Nature Genetics · doi:10.1038/ng.2823 · Cited by 1,145
Adjuvant Ovarian Suppression in Premenopausal Breast Cancer
Francis, P. A., Regan, M. M., Fleming, G. F., Láng, I., Ciruelos, E., Bellet, M., Bonnefoi, H. R., Climent, M. A., Da Prada, G. A., Burstein, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412379 · Cited by 726
Cited by
Items 301–400 of 1,000
Toward precision medicine of breast cancer
Carels, N., Spinassé, L. B., Tilli, T. M., & Tuszyński, J. A. (2016) · Theoretical Biology and Medical Modelling · doi:10.1186/s12976-016-0035-4 · Cited by 70
CDK4 regulates cancer stemness and is a novel therapeutic target for triple-negative breast cancer
Dai, M., Zhang, C., Ali, A., Hong, X., Tian, J., Lo, C., Fils-Aimé, N., Burgos, S. A., Ali, S., & Lebrun, J. J. (2016) · Scientific Reports · doi:10.1038/srep35383 · Cited by 65
Kim, S. S., Armand, J., Safonov, A. M., Zhang, M., Soni, R. K., Schwartz, G. K., McGuinness, J. E., Hibshoosh, H. H., Razavi, P., Kim, M., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.113198 · Cited by 69
“8–10 However, the efficacy of CDK4/6i is highly variable, and no biomarkers are available to predict treatment response.”
BackgroundCaruso, J. A., Duong, M. T., Carey, J. P. W., Hunt, K. K., & Keyomarsi, K. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-1235 · Cited by 69
RB1 Heterogeneity in Advanced Metastatic Castration-Resistant Prostate Cancer
Rodrigues, D. N., Casiraghi, N. A., Romanel, A., Crespo, M., Miranda, S., Rescigno, P., Figueiredo, I., Riisnaes, R., Carreira, S., Sumanasuriya, S., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2068 · Cited by 66
Breast Cancer Therapeutics and Biomarkers: Past, Present, and Future Approaches
Schick, J., Ritchie, R. P., & Restini, C. B. A. (2021) · Breast Cancer Basic and Clinical Research · doi:10.1177/1178223421995854 · Cited by 74
Current Trends in the Treatment of HR+/HER2+ Breast Cancer
Kay, C., Martínez-Pérez, C., Meehan, J., Gray, M., Webber, V. L., Dixon, J. M., & Turnbull, A. (2021) · Future Oncology · doi:10.2217/fon-2020-0504 · Cited by 65
The Growing Role of CDK4/6 Inhibitors in Treating Hormone Receptor-Positive Advanced Breast Cancer
Shah, A. N., & Cristofanilli, M. (2017) · Current Treatment Options in Oncology · doi:10.1007/s11864-017-0443-7 · Cited by 71
Self-citationBattisti, N. M. L., de Glas, N. A., Sedrak, M. S., Loh, K. P., Liposits, G. I., Soto‐Pérez‐de‐Celis, E., Krok‐Schoen, J. L., Menjak, I. B., & Ring, A. E. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835918809610 · Cited by 65
Fujiwara, Y., Tamura, K., Kondo, S., Tanabe, Y., Iwasa, S., Shimomura, A., Kitano, S., Ogasawara, K., Turner, P. K., Mori, J., et al. (2016) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-016-3085-8 · Cited by 66
Progress with palbociclib in breast cancer: latest evidence and clinical considerations
Rocca, A., Schirone, A., Maltoni, R., Bravaccini, S., Cecconetto, L., Farolfi, A., Bronte, G., & Andreis, D. (2016) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834016677961 · Cited by 69
Breast Cancer Biology: Clinical Implications for Breast Radiation Therapy
Horton, J. K., Jagsi, R., Woodward, W. A., & Ho, A. Y. (2017) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2017.08.025 · Cited by 65
Arnedos, M., Bayar, M. A., Cheaib, B., Scott, V., Bouakka, I., Valent, A., Adam, J., Leroux-Kozal, V., Marty, V., Rapinat, A., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy202 · Cited by 64
Self-citationNeuroendocrine breast carcinoma: a rare but challenging entity
Trevisi, E., Salvia, A. L., Daniele, L., Brizzi, M. P., Rosa, G. D., Scagliotti, G. V., & Maïo, M. D. (2020) · Medical Oncology · doi:10.1007/s12032-020-01396-4 · Cited by 67
Hartkopf, A. D., Huober, J., Volz, B., Nabieva, N., Taran, F., Schwitulla, J., Overkamp, F., Kolberg, H., Hadji, P., Tesch, H., et al. (2017) · The Breast · doi:10.1016/j.breast.2017.10.002 · Cited by 61
Inhibitors targeting CDK4/6, PARP and PI3K in breast cancer: a review
Husna, S. M. N., Tan, H. T., Mohamud, R., Dyhl-Polk, A., & Wong, K. K. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835918808509 · Cited by 71
The era of high-quality chemical probes
Licciardello, M. P., & Workman, P. (2022) · RSC Medicinal Chemistry · doi:10.1039/d2md00291d · Cited by 77
Solzak, J. P., Atale, R. V., Hancock, B. A., Sinn, A. L., Pollok, K. E., Jones, D. R., & Radovich, M. (2017) · npj Breast Cancer · doi:10.1038/s41523-017-0016-8 · Cited by 65
To Cycle or Fight—CDK4/6 Inhibitors at the Crossroads of Anticancer Immunity
Ameratunga, M., Kipps, E., Okines, A. F. C., & Lopez, J. S. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1999 · Cited by 62
Genome-Wide Estrogen Receptor Activity in Breast Cancer
Farcas, A. M., Nagarajan, S., Cosulich, S. C., & Carroll, J. S. (2020) · Endocrinology · doi:10.1210/endocr/bqaa224 · Cited by 66
Cyclin-dependent kinase inhibitors for the treatment of breast cancer: past, present, and future
DiPippo, A. J., Patel, N. K., & Barnett, C. M. (2016) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1756 · Cited by 60
Martin, J., Handorf, E. A., Montero, A. J., & Goldstein, L. J. (2022) · The Oncologist · doi:10.1093/oncolo/oyac075 · Cited by 67
AACR Cancer Progress Report 2015
Baselga, J., Bhardwaj, N., Cantley, L. C., DeMatteo, R., DuBois, R. N., Foti, M., Gapstur, S. M., Hahn, W. C., Helman, L. J., Jensen, R. A., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1846 · Cited by 55
Schneeweiß, A., Ettl, J., Lüftner, D., Beckmann, M. W., Belleville, E., Fasching, P. A., Fehm, T. N., Geberth, M., Häberle, L., Hadji, P., et al. (2020) · The Breast · doi:10.1016/j.breast.2020.08.011 · Cited by 61
Masuda, N., Inoue, K., Nakamura, R., Rai, Y., Mukai, H., Ohno, S., Hara, F., Mori, Y., Hashigaki, S., Muramatsu, Y., et al. (2018) · International Journal of Clinical Oncology · doi:10.1007/s10147-018-1359-3 · Cited by 66
Self-citationCCNE1 and PLK1 Mediate Resistance to Palbociclib in HR+/HER2− Metastatic Breast Cancer
Zotano, Á. G., Belli, S., Zielinski, C. C., Gil‐Gil, M., Fernández‐Serra, A., Ruíz-Borrego, M., Ciruelos, E., Pascual, J., Muñoz-Mateu, M., Bermejo, B., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-2206 · Cited by 60
Self-citationXiao, L., Liu, Y., Chen, H., & Shen, L. (2023) · Cancer Biology & Therapy · doi:10.1080/15384047.2023.2219470 · Cited by 61
Deciphering and Targeting Oncogenic Mutations and Pathways in Breast Cancer
Santarpia, L., Bottai, G., Kelly, C. M., Győrffy, B., Székely, B., & Pusztai, L. (2016) · The Oncologist · doi:10.1634/theoncologist.2015-0369 · Cited by 64
Neoadjuvant Therapy for Breast Cancer: Established Concepts and Emerging Strategies
Steenbruggen, T. G., van Ramshorst, M. S., Kok, M., Linn, S. C., Smorenburg, C. H., & Sonke, G. S. (2017) · Drugs · doi:10.1007/s40265-017-0774-5 · Cited by 64
Wu, H., & Chu, P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020636 · Cited by 64
“3% of patients from the Study of Faslodex Versus Exemestane with or without Arimidex (SoFEA) trial and the PALOMA-3 trial [186], respectively.”
BackgroundRelevance of pRB Loss in Human Malignancies
Mandigo, A. C., Tomlins, S. A., Kelly, W. K., & Knudsen, K. E. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1565 · Cited by 62
Breast Cancer and Tumor Microenvironment: The Crucial Role of Immune Cells
Moura, T., Laranjeira, P., Caramelo, O. L., Gil, A. M., & Paiva, A. A. (2025) · Current Oncology · doi:10.3390/curroncol32030143 · Cited by 61
“In cases of resistance to endocrine therapy, CDK4/6 inhibitors, such as palbociclib, have been integrated into treatment strategies to prevent cell cycle progression [187,189].”
participants, O. B. O. T. I. T., Palmieri, C., Stein, R. C., Liu, X., Hudson, E., Nicholas, H., Sasano, H., Guestini, F., Holcombe, C., Barrett, S., et al. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4328-z · Cited by 55
Impact of Complex Apoptotic Signaling Pathways on Cancer Cell Sensitivity to Therapy
Kim, R., Kin, T., & Beck, W. T. (2024) · Cancers · doi:10.3390/cancers16050984 · Cited by 69
“The use of the CDK4/6 inhibitors palbociclib [186], ribociclib [187], and abemaci-clib [188] as first-or second-line therapy confers survival benefits for patients with HR-positive/HER2-negative advanced breast cancer.”
MethodLayman, R. M., Han, H. S., Rugo, H. S., Stringer-Reasor, E. M., Specht, J. M., Dees, E. C., Kabos, P., Suzuki, S., Mutka, S. C., Sullivan, B. F., et al. (2024) · The Lancet Oncology · doi:10.1016/s1470-2045(24)00034-2 · Cited by 59
Neoadjuvant palbociclib on ER+ breast cancer (N007): clinical response and EndoPredict’s value
Chow, L. W., Morita, S., Chow, C. Y. C., Ng, W.-K., & Toi, M. (2017) · Endocrine Related Cancer · doi:10.1530/erc-17-0396 · Cited by 57
Breast cancer tumor histopathology, stage at presentation, and treatment in the extremes of age
Plichta, J. K., Thomas, S. M., Vernon, R. L., Fayanju, O. M., Rosenberger, L. H., Hyslop, T., Hwang, E. S., & Greenup, R. A. (2020) · Breast Cancer Research and Treatment · doi:10.1007/s10549-020-05542-4 · Cited by 57
Tannock, I. F., Pond, G. R., & Booth, C. M. (2022) · JAMA Oncology · doi:10.1001/jamaoncol.2021.8206 · Cited by 58
A role of FDG-PET/CT for response evaluation in metastatic breast cancer?
Hildebrandt, M. G., Naghavi‐Behzad, M., & Vogsen, M. (2022) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2022.03.004 · Cited by 59
Molecular Mechanisms of Anti-Estrogen Therapy Resistance and Novel Targeted Therapies
Özyurt, R., & Özpolat, B. (2022) · Cancers · doi:10.3390/cancers14215206 · Cited by 63
The therapeutic potential of neurofibromin signaling pathways and binding partners
Báez-Flores, J., Rodríguez-Martín, M., & Lacal, J. (2023) · Communications Biology · doi:10.1038/s42003-023-04815-0 · Cited by 58
Development of Companion Diagnostics
Mankoff, D. A., Edmonds, C. E., Farwell, M. D., & Pryma, D. A. (2015) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2015.09.002 · Cited by 59
Genomics of gallbladder cancer: the case for biomarker-driven clinical trial design
Sicklick, J. K., Fanta, P. T., Shimabukuro, K. A., & Kurzrock, R. (2016) · Cancer and Metastasis Reviews · doi:10.1007/s10555-016-9602-8 · Cited by 59
Sousa, B., Ribeiro, J. M., Ribnikar, D., & Cardoso, F. (2016) · Springer eBooks · doi:10.1007/978-3-319-46356-8_24 · Cited by 57
Cost-effectiveness of palbociclib in hormone receptor-positive advanced breast cancer
Mamiya, H., Tahara, R. K., Tolaney, S. M., Choudhry, N. K., & Najafzadeh, M. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx201 · Cited by 58
Inhibition of nuclear Wnt signalling: challenges of an elusive target for cancer therapy
Lyou, Y., Habowski, A. N., Chen, G. T., & Waterman, M. L. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13963 · Cited by 58
Impact of somatic and germline mutations on the outcome of systemic mastocytosis
Muñoz-González, J. I., Jara-Acevedo, M., Alvarez-Twose, I., Merker, J. D., Teodosio, C., Hou, Y., Henriques, A., Roskin, K. M., Sanchez-Muñoz, L., Tsai, A. G., et al. (2018) · Blood Advances · doi:10.1182/bloodadvances.2018020628 · Cited by 55
Current Therapeutic Progress of CDK4/6 Inhibitors in Breast Cancer
Wu, Y., Zhang, Y., Pi, H., & Sheng, Y. (2020) · Cancer Management and Research · doi:10.2147/cmar.s250632 · Cited by 60
Bonechi, M., Galardi, F., Biagioni, C., Luca, F. D., Bergqvist, M., Neumüller, M., Guarducci, C., Boccalini, G., Gabellini, S., Migliaccio, I., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.24700 · Cited by 55
Navarro-Yepes, J., Kettner, N. M., Rao, X., Bishop, C. S., Bui, T. N., Wingate, H. F., Raghavendra, A. S., Wang, Y., Wang, J., Şahin, A. A., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-23-0705 · Cited by 59
Next-Generation ERα Inhibitors for Endocrine-Resistant ER+ Breast Cancer
Fanning, S. W., & Greene, G. L. (2019) · Endocrinology · doi:10.1210/en.2018-01095 · Cited by 55
Current Molecular Targeted Therapies for Bone and Soft Tissue Sarcomas
Nakano, K., & Takahashi, S. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19030739 · Cited by 59
Kümler, I., Knoop, A. S., Jessing, C., Ejlertsen, B., & Nielsen, D. L. (2016) · ESMO Open · doi:10.1136/esmoopen-2016-000062 · Cited by 57
Update on cardio-oncology: Novel cancer therapeutics and associated cardiotoxicities
Guha, A., Armanious, M. A., & Fradley, M. G. (2018) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2018.06.001 · Cited by 56
Triple-negative breast cancer: new treatment strategies in the era of precision medicine
Wu, S., Wang, H., Shao, Z., & Jiang, Y. (2020) · Science China Life Sciences · doi:10.1007/s11427-020-1714-8 · Cited by 62
Dai, M., Boudreault, J., Wang, N., Poulet, S., Daliah, G., Yan, G., Moamer, A., Burgos, S. A., Sabri, S., Ali, S., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-2121 · Cited by 57
Kassem, L. M. H., Shohdy, K. S., Lasheen, S., Abdel-Rahman, O. M., & Bachelot, T. (2017) · Breast Cancer · doi:10.1007/s12282-017-0818-4 · Cited by 58
Endocrine Therapy for Breast Cancer in the Primary Care Setting
Awan, A. A., & Esfahani, K. (2018) · Current Oncology · doi:10.3747/co.25.4139 · Cited by 60
Palbociclib: A Review in HR-Positive, HER2-Negative, Advanced or Metastatic Breast Cancer
Kim, E., & Scott, L. J. (2017) · Targeted Oncology · doi:10.1007/s11523-017-0492-7 · Cited by 54
Xiong, Y., Li, T., Assani, G., Ling, H., Zhou, Q., Zeng, Y., Zhou, F., & Zhou, Y. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.108602 · Cited by 54
Goyal, R., Chen, H., Abughosh, S., Holmes, H. M., Candrilli, S. D., & Johnson, M. L. (2023) · Cancer · doi:10.1002/cncr.34675 · Cited by 52
Grinshpun, A., Tolaney, S. M., Burstein, H. J., Jeselsohn, R. M., & Mayer, E. L. (2023) · npj Breast Cancer · doi:10.1038/s41523-023-00520-7 · Cited by 56
Pavlovic, D., Nićiforović, D., Papic, D., Milojevic, K., & Marković, M. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231205848 · Cited by 57
Bertucci, F., Finetti, P., Gonçalvès, A., & Birnbaum, D. (2020) · npj Breast Cancer · doi:10.1038/s41523-020-0151-5 · Cited by 62
Migliaccio, I., Bonechi, M., McCartney, A., Guarducci, C., Benelli, M., Biganzoli, L., Leo, A. D., & Malorni, L. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102136 · Cited by 60
Mater, D. V., Gururangan, S., Becher, O. J., Campagne, O., Leary, S. E. S., Phillips, J. J., Huang, J., Lin, T., Poussaint, T. Y., Goldman, S., et al. (2021) · Pediatric Blood & Cancer · doi:10.1002/pbc.28879 · Cited by 51
Berger, F., Marce, M., Delaloge, S., Bessard, A. C. H., Bachelot, T., Bièche, I., Pradines, A., Rouge, T. D. L. M., Canon, J.-L. R., André, F., et al. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-055821 · Cited by 57
Self-citationIsmail, R. K., van Breeschoten, J., Wouters, M. W. J. M., van Dartel, M., van der Flier, S., Reyners, A. K. L., de Graeff, P., Pasmooij, A. M. G., de Boer, A., Broekman, K. E., et al. (2021) · The Breast · doi:10.1016/j.breast.2021.11.013 · Cited by 51
Bruno, L. I., Ostinelli, A., Waisberg, F., Enrico, D. H., Ponce, C., Rivero, S. G., Blanco, A., Zarbá, M., Loza, M., Fabiano, V., et al. (2022) · JCO Precision Oncology · doi:10.1200/po.21.00140 · Cited by 54
Seftel, M. D., Kuruvilla, J. G., Kouroukis, T., Banerji, V., Fraser, G. A. M., Crump, M., Kumar, R., Chalchal, H. I., Salim, M., Laister, R. C., et al. (2016) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2016.1239259 · Cited by 51
CDK4/6 inhibitors in HER2-positive breast cancer
Corona, S. P., Ravelli, A., Cretella, D., Cappelletti, M. R., Zanotti, L., Dester, M., Gobbi, A., Petronini, P. G., & Generali, D. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.02.022 · Cited by 53
Treatment for the endocrine resistant breast cancer: Current options and future perspectives
Liu, C., Wu, C., Petrossian, K., Huang, T., Tseng, L., & Chen, S. (2017) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2017.07.001 · Cited by 55
Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer: Redrawing the Lines
Matutino, A. R. B., Joy, A. A., Brezden‐Masley, C., Chia, S., & Verma, S. (2018) · Current Oncology · doi:10.3747/co.25.4000 · Cited by 56
Self-citationPatient-Derived Xenograft Models for Endometrial Cancer Research
Moiola, C. P., López-Gil, C., Cabrera, S., García, Á., Nyen, T. V., Annibali, D., Fonnes, T., Vidal, A., Villanueva, A., Matías‐Guiu, X., et al. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19082431 · Cited by 52
“The use of palbociclib against the cyclin-dependent kinases CDK4 and CDK6 has successfully been used in advanced breast cancer [58] and it is under evaluation in many other cancer types in phase II and III clinical trials [59].”
MethodLiu, P., Tang, Q., Chen, M., Chen, W., Lu, Y., Liu, Z., & He, Z. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.589908 · Cited by 56
“Food and Drug Administration for clinical treatment of advanced breast cancer (32).”
BackgroundCDK4/6 and MAPK—Crosstalk as Opportunity for Cancer Treatment
Scheiblecker, L., Kollmann, K., & Sexl, V. (2020) · Pharmaceuticals · doi:10.3390/ph13120418 · Cited by 55
Kawamoto, T., Shikama, N., & Sasai, K. (2018) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2018.09.020 · Cited by 50
ESR1 F404 Mutations and Acquired Resistance to Fulvestrant in ESR1 -Mutant Breast Cancer
Kingston, B., Pearson, A., Herrera-Abreu, M. T., Sim, L.-X., Cutts, R. J., Shah, H. P., Moretti, L., Kilburn, L., Johnson, H., Macpherson, I. R., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-1387 · Cited by 53
Self-citationHsu, C., Lin, L., Cheng, Y., Feng, Z.-R., Shao, Y., Cheng, A., & Ou, D. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0499 · Cited by 50
Ahn, D. H., Javle, M. M., Ahn, C. W., Jain, A., Mikhail, S., Noonan, A. M., Wu, C. S.-Y., Shroff, R. T., Chen, J. L., & Bekaii‐Saab, T. (2016) · Cancer · doi:10.1002/cncr.30247 · Cited by 49
Gyanchandani, R., Kota, K. J., Jonnalagadda, A. R., Minteer, T., Knapick, B. A., Oesterreich, S., Brufsky, A., Lee, A. V., & Puhalla, S. L. (2016) · Oncotarget · doi:10.18632/oncotarget.11383 · Cited by 50
Breast Cancer in the Central Nervous System: Multidisciplinary Considerations and Management
Lin, N., Gaspar, L. E., & Soffietti, R. (2017) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_175338 · Cited by 51
Ongoing unmet needs in treating estrogen receptor-positive/HER2-negative metastatic breast cancer
Başaran, G., Twelves, C. J., Dieras, V. C., Cortés, J., & Awada, A. H. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.12.002 · Cited by 51
Thangavel, C., Boopathi, E., Liu, Y., McNair, C. M., Haber, A. O., Perepelyuk, M., Bhardwaj, A., Addya, S., Ertel, A., Shoyele, S., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2074 · Cited by 53
Janni, W., Alba, E., Bachelot, T., Diab, S., Gil‐Gil, M., Beck, T., Ryvo, L., López‐López, R., Tsai, M. L., Esteva, F. J., et al. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4658-x · Cited by 51
Raschi, E., & De Ponti, F. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01235 · Cited by 48
Vitamin D receptor (VDR) and metabolizing enzymes CYP27B1 and CYP24A1 in breast cancer
Voutsadakis, I. A. (2020) · Molecular Biology Reports · doi:10.1007/s11033-020-05780-1 · Cited by 49
Harbeck, N., Fasching, P. A., Wuerstlein, R., Degenhardt, T., Lüftner, D., Kates, R. E., Schumacher, J., Räth, P., Hoffmann, O., Lorenz, R., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.05.003 · Cited by 56
Self-citationMangini, N. S., Wesolowski, R., Ramaswamy, B., Lustberg, M. B., & Berger, M. J. (2015) · Annals of Pharmacotherapy · doi:10.1177/1060028015602273 · Cited by 55
Kaklamani, V., & Gradishar, W. J. (2017) · The Oncologist · doi:10.1634/theoncologist.2015-0464 · Cited by 53
“…2.5 mg daily 444 42.1 NR 24.8 (p< .001) Letrozole, 2.5 mg daily 222 34.7 NR 14.5 Palbociclib1 fulvestrant (HD) as second-line combination treatment Turner et al. 2015 PALOMA-3 [93] Palbociclib, 125 mg daily for 3 weeks, 1 week off over 28-day cycles1 Fulvestrant, 500 mg day 1; 500 mg days 15 and…”
InfluentialGenetic Characterization of Brain Metastases in the Era of Targeted Therapy
Han, C. H., & Brastianos, P. K. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00230 · Cited by 53
Combination Paclitaxel and Palbociclib: Results of a Phase I Trial in Advanced Breast Cancer
Clark, A. S., McAndrew, N. P., Troxel, A. B., Feldman, M. D., Lal, P., Rosen, M. A., Burrell, J. A., Redlinger, C., Gallagher, M., Bradbury, A. R., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0790 · Cited by 49
Zhao, Z., Li, Y., Shukla, R., Liu, H., Jain, A., Barve, A. J., & Cheng, K. (2019) · Theranostics · doi:10.7150/thno.34314 · Cited by 47
CDK4/6 inhibitors in the treatment of metastatic breast cancer: Focus on toxicity and safety
Wekking, D., Lambertini, M., Dessì, M., Denaro, N., Bardanzellu, F., Garrone, O., Scartozzi, M., & Solinas, C. (2023) · Seminars in Oncology · doi:10.1053/j.seminoncol.2024.01.002 · Cited by 55
Nikolai, B. C., Lanz, R. B., York, B., Dasgupta, S., Mitsiades, N., Creighton, C. J., Tsimelzon, A. I., Hilsenbeck, S. G., Lonard, D. M., Smith, C. S., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2383 · Cited by 49
Preusser, M., Mattos‐Arruda, L. D., Thill, M., Criscitiello, C., Bartsch, R., Ruhstaller, T., de Azambuja, E., & Zielinski, C. C. (2018) · ESMO Open · doi:10.1136/esmoopen-2018-000368 · Cited by 49
Palbociclib for the Treatment of Estrogen Receptor–Positive, HER2-Negative Metastatic Breast Cancer
Morikawa, A., & Henry, N. L. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0390 · Cited by 50
Johnston, S. R. D., Basik, M., Hegg, R., Lausoontornsiri, W., Grzeda, L., Clemons, M. J., Dreosti, L., Mann, H., Stuart, M., & Cristofanilli, M. (2016) · Breast Cancer Research and Treatment · doi:10.1007/s10549-016-3979-5 · Cited by 49
Self-citationHormonoresistance in advanced breast cancer: a new revolution in endocrine therapy
Augereau, P., Patsouris, A., Bourbouloux, E., Gourmelon, C., Lacourtoisie, S. A., Rigaud, D. B., Soulié, P., Frenel, J., & Campone, M. (2017) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834017693195 · Cited by 50
VGLL4 interacts with STAT3 to function as a tumor suppressor in triple-negative breast cancer
Song, H., Luo, Q., Deng, X., Ji, C., Li, D., Munankarmy, A., Jian, W., Zhao, J., & Fang, L. (2019) · Experimental & Molecular Medicine · doi:10.1038/s12276-019-0338-8 · Cited by 49
Metadata
- Authors
- Turner, N. C., Ro, J., André, F., Loi, S., Verma, S., Iwata, H., Harbeck, N., Loibl, S., Huang Bartlett, C., Zhang, K., Giorgetti, C., Randolph, S., Koehler, M., & Cristofanilli, M.
- Affiliations
- Sunnybrook Health Science Centre (CA)
- National Cancer Center (KR)
- Institut Gustave Roussy (FR)
- The University of Melbourne (AU)
- Aichi Cancer Center Hospital (JP)
- Ludwig-Maximilians-Universität München (DE)
- German Breast Group (DE)
- Pfizer (United States) (US)
- Thomas Jefferson University (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-07-16
- Volume
- 373
- Issue
- 3
- Pages
- 209-219
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1464936406
- Cited by
- 1,590
- References
- 26
- Citations by year
- 2026: 67 · 2025: 142 · 2024: 117 · 2023: 109 · 2022: 127 · 2021: 142 · 2020: 172 · 2019: 123 · 2018: 169 · 2017: 193 · 2016: 179 · 2015: 49
- FWCI
- 154.46
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research Publications (Maastricht University) (publishedVersion, other-oa)
- The Medicine Forum (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Research Publications (Maastricht University) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Keywords
- palbociclib, hormone receptor-positive breast cancer, HER2-negative breast cancer, CDK4/6 inhibitors, fulvestrant, progression-free survival, endocrine therapy resistance, neutropenia, febrile neutropenia, goserelin, metastatic breast cancer, G1/S transition, adverse events, overall survival
- MeSH terms
- Fulvestrant, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Double-Blind Method, Estradiol, Female, Humans, Middle Aged, Piperazines, Pyridines, Receptors, Estrogen, Receptors, Progesterone, Biomarkers, Disease-Free Survival, Erb-b2 Receptor Tyrosine Kinases, Protein Kinase Inhibitors, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.